[Congressional Record Volume 168, Number 198 (Tuesday, December 20, 2022)]
[Senate]
[Pages S9613-S9614]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
CHILDHOOD CANCER SURVIVORSHIP, TREATMENT, ACCESS, AND RESEARCH
REAUTHORIZATION ACT OF 2022
Mr. HEINRICH. Mr. President, I ask unanimous consent that the
Committee on Health, Education, Labor, and Pensions be discharged from
further consideration of S. 4120 and the Senate proceed to its
immediate consideration.
The PRESIDING OFFICER. The clerk will report the bill by title.
The senior assistant legislative clerk read as follows:
A bill (S. 4120) to maximize discovery, and accelerate
development and availability, of promising childhood cancer
treatments, and for other purposes.
There being no objection, the committee was discharged, and the
Senate proceeded to consider the bill.
Mr. HEINRICH. I ask unanimous consent that the Reed substitute
amendment at the desk be considered and agreed to; that the bill, as
amended, be considered read a third time and passed; and that the
motion to reconsider be considered made and laid upon the be table.
The PRESIDING OFFICER. Without objection, it is so ordered.
The amendment (No. 6584) in the nature of a substitute was agreed to,
as follows:
(Purpose: In the nature of a substitute)
Strike all after the enacting clause and insert the
following:
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Childhood Cancer
Survivorship, Treatment, Access, and Research Reauthorization
Act of 2022'' or the ``Childhood Cancer STAR Reauthorization
Act''.
SEC. 2. REAUTHORIZING AND IMPROVING THE CHILDHOOD STAR ACT.
(a) Children's Cancer Biorepositories.--Section 417E of the
Public Health Service Act (42 U.S.C. 285a-11) is amended--
(1) in subsection (a)--
(A) in paragraph (2)(A), by inserting before the period at
the end of the second sentence the following: ``, such as
collected samples of both solid tumor cancer and paired
samples'';
(B) in paragraph (9), by striking ``Childhood Cancer
Survivorship, Treatment, Access, and Research Act of 2018''
and inserting ``Childhood Cancer Survivorship, Treatment,
Access, and Research Reauthorization Act of 2022'';
(C) by redesignating paragraph (10) as paragraph (11); and
(D) by inserting after paragraph (9) the following:
``(10) Report on researcher access to children's cancer
biorepository samples.--Not later than 2 years after the date
of enactment of the Childhood Cancer Survivorship, Treatment,
Access, and Research Reauthorization Act of 2022, the
Director of NIH shall--
``(A) conduct a review of the procedures established under
paragraph (2)(C) and other policies or procedures related to
researcher access to such biospecimens to identify any
opportunities to reduce administrative burden, consistent
with paragraph (2)(D), in a manner that protects personal
privacy to the extent required by applicable Federal and
State privacy law, at a minimum; and
``(B) submit to the Committee on Health, Education, Labor,
and Pensions of the Senate and the Committee on Energy and
Commerce of the House of Representatives a report on the
findings of the review under subparagraph (A) and whether the
Director of NIH plans to make any changes to the policies or
procedures considered in such review, based on such
findings.''; and
(2) in subsection (d), by striking ``2019 through 2023''
and inserting ``2024 through 2028''.
(b) Cancer Survivorship Programs.--Section 201 of the
Childhood Cancer Survivorship, Treatment, Access, and
Research Act of 2018 (Public Law 115-180) is amended--
(1) in subsection (a)--
(A) in the subsection heading, by striking ``Pilot Programs
to Explore'' and inserting ``Research to Evaluate''
(B) in paragraph (1)--
(i) by striking ``may make awards to eligible entities to
establish pilot programs'' and inserting ``shall, as
appropriate, make awards to eligible entities to conduct or
support research'';
(ii) by striking ``model systems'' and inserting
``approaches'';
(iii) by inserting ``and adolescent'' after ``childhood'';
and
(iv) by striking ``evaluation of models for'';
(C) in paragraph (2)--
(i) in subparagraph (A), in the matter preceding clause
(i), by inserting ``within the
[[Page S9614]]
existing peer review process,'' after ``practicable,''; and
(ii) in subparagraph (B)(v), by striking ``in treating
survivors of childhood cancers'' and inserting ``in carrying
out the activities described in paragraph (1)''; and
(D) in paragraph (3)(B)(v), by striking ``design of systems
for the effective transfer of treatment information and care
summaries from cancer care providers to other health care
providers'' and inserting ``design tools to support the
secure electronic transfer of treatment information and care
summaries between health care providers or, as applicable and
appropriate, longitudinal childhood cancer survivorship
cohorts''; and
(2) in subsection (b)--
(A) in each of paragraphs (1) and (2), by striking ``date
of enactment of this Act'' and inserting ``date of enactment
of the Childhood Cancer Survivorship, Treatment, Access, and
Research Reauthorization Act of 2022''; and
(B) in paragraph (1)--
(i) by striking subparagraphs (A) and (C);
(ii) by redesignating subparagraph (B) as subparagraph (A);
and
(iii) by adding at the end the following:
``(B) recommendations for enhancing or promoting activities
of the Department of Health and Human Services related to
workforce development for health care providers who provide
psychosocial care to pediatric cancer patients and
survivors.''.
The bill (S. 4120), as amended, was ordered to be engrossed for a
third reading, was read the third time, and passed.
____________________